Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Leukemia & Lymphoma|August 12, 2024
Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective studyAndrée-Anne Pelland, Xavier Deschênes-Simard, Xavier Savard, et al.
British Journal of Haematology|December 6, 2019
Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapyDaniel J Landsburg, Emily C Ayers, David A Bond, et al.
Blood Advances|February 5, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformationKatharine Louise Lewis, Sarit E Assouline, Ross Ian Baker, et al.
Blood|December 4, 2023
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomasStephen J Schuster, Ling-Yuh Huw, Christopher R Bolen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 5, 2014
Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trialsTorsten Holm Nielsen, Zuanel Diaz, Rosa Christodoulopoulos, et al.
Blood|October 24, 2024
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapiesLaurie H Sehn, Nancy L Bartlett, Matthew J Matasar, et al.
Blood|February 26, 2025
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLLArnon P Kater, Rosemary Anne Harrup, Thomas J Kipps, et al.
Blood|May 12, 2016
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphomaSarit E Assouline, Torsten Holm Nielsen, Stephen Yu, et al.
Blood|April 21, 2026
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 studyLihua E Budde, Manali Kamdar, Sarit E Assouline, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2019
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin LymphomaIan W Flinn, Carole B Miller, Kirit M Ardeshna, et al.
Pageof 3